Findings

What do systematic reviews say?

266 questions · 274 findings · 25 reviews · Movement Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13 · 4.7%GRADE not reported 7 · 2.6%Very low 66 · 24.1%Low 66 · 24.1%Moderate 87 · 31.8%High 35 · 12.8%

Summary of findings: levodopa vs other dopamine agonists

IRLS · patients with restless legs syndrome

1 finding from 1 review

Levodopa for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 383 participants
Moderate

Summary of findings: levodopa vs other dopamine agonists

Periodic limb movements per hour of time in bed · patients with restless legs syndrome

1 finding from 1 review

Levodopa for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Dopamine agonist vs placebo

IRLS · patients with restless legs syndrome according to IRLSSG, 18 years or older

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
30 studies · 6380 participants
Moderate

Dopamine agonist vs levodopa

Adverse effects (drop‐outs due to adverse effects4) · patients with restless legs syndrome

Summary of findings: dopamine agonists probably leads to higher number of drop outs due to adverse events compared with levodopa (moderate certainty).

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
OR 1.7
3 studies · 504 participants
Moderate

Dopamine agonist vs levodopa

Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · patients with restless legs syndrome

Summary of findings: dopamine agonists showed no clear difference in clinical Global Impressions ‐ Improvement of condition (CGI‐I)… compared with levodopa (moderate certainty).

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
RR 1.19 [0.91, 1.56]
2 studies · 422 participants
Moderate

Dopamine agonist vs levodopa

Quality of sleep · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 344 participants
Low

Dopamine agonist vs levodopa

QoL · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 314 participants
Moderate

Dopamine agonist vs levodopa

Number of participants reporting an adverse event · patients with restless legs syndrome

Summary of findings: dopamine agonists showed no clear difference in number of patients experiencing adverse events compared with levodopa (moderate certainty).

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
OR 2.87 [0.43, 19]
3 studies · 461 participants
Moderate

Intervention not reported

IRLS all dopamine agonists · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
30 studies · 6380 participants
Moderate

Intervention not reported

IRLS cabergoline · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 127 participants
High

Intervention not reported

IRLS lisuride · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 378 participants
High

Intervention not reported

IRLS pergolide · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 97 participants
High

Intervention not reported

IRLS pramipexole · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 2256 participants
Moderate

Dopamine agonist vs placebo

Periodic limb movements in sleep (PLMS Index) PLMS per hour of sleep (8 trials) or time in bed (7 trials) · patients with restless legs syndrome according to IRLSSG, 18 years or older

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 1141 participants
Moderate

Intervention not reported

IRLS ropinirole · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 2301 participants
Moderate

Intervention not reported

IRLS rotigotine · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 958 participants
High

Intervention not reported

IRLS sumanirole · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 263 participants
High

Dopamine agonist vs placebo

Sleep efficiency · patients with restless legs syndrome according to IRLSSG, 18 years or older

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 677 participants
High

Dopamine agonist vs placebo

Withdrawals due to adverse events · patients with restless legs syndrome according to IRLSSG, 18 years or older

Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
OR 1.82 [1.35, 2.45]
34 studies · 7054 participants
High

Dopamine agonist vs placebo

Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · patients with restless legs syndrome according to IRLSSG, 18 years or older

Summary of findings: dopamine agonists leads to higher clinical Global Impressions ‐ Improvement of condition (CGI‐I)… compared with placebo (high certainty).

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
RR 1.44 [1.34, 1.54]
27 studies · 6338 participants
High